Adaptive Biotechnologies Beats Q2 Revenue, Lifts MRD Guidance, and Plans Business Separation
ADPT has more than doubled off its 52-week low of $10.19.
Summary
Adaptive Biotechnologies delivered strong Q2 results with revenue of $71.6M, beating estimates, and raised its full-year MRD revenue outlook. The company also announced plans to separate its Immune Medicine and MRD businesses by year-end.
Key Events · Earnings and Guidance · ADPT
-
Q2 Revenue Beat
Revenue reached $71.6M, up 22% YoY and ahead of the $65.9M consensus, driven by a 43% increase in clonoSEQ test volume to 36,111 tests.
-
Raised MRD Guidance
Full-year MRD revenue guidance was raised, reflecting strong commercial execution and robust demand for clonoSEQ.
-
Business Separation Announced
A formal plan to separate the Immune Medicine and MRD businesses was announced, with a preferred path expected by year-end 2026. As part of this, Immune Medicine will wind down Adaptive Immunosequencing services in H2 2026.
-
Non-Cash Loss on Debt Extinguishment
The net loss of $39.9M includes a $23.7M non-cash charge from the early settlement of the OrbiMed revenue interest liability, not an operational deterioration.
Analysis · ADPT · Life Sciences
A 22% year-over-year revenue jump to $71.6 million, exceeding consensus estimates, underscores the strength of Adaptive Biotechnologies' clonoSEQ franchise, where test volume surged 43%. Confidence in this commercial momentum prompted a raise in full-year MRD revenue guidance. While the net loss widened to $39.9 million, $23.7 million of that stemmed from a non-cash charge tied to extinguishing a legacy revenue interest liability—not a sign of operational weakness. Following the June convertible notes offering, cash and equivalents sit at $371.7 million, providing ample runway. Management also formalized plans to separate the Immune Medicine and MRD businesses, with a preferred path expected by year-end, and will wind down the lower-margin Adaptive Immunosequencing services in the second half of 2026. The separation is designed to unlock value but introduces execution risk, as flagged in a new risk factor. Trading near its 52-week high, the stock reflects market optimism around the MRD franchise.
At the time of this filing, ADPT was trading at $24.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $10.19 to $24.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.